Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer

DOI Full Paper Access

11

Citations

10

References

2016

Year

Chao Huang, Stephen K. Williamson, Prakash Neupane, Sarah A. Taylor, Ace Allen, Nora J. Smart, Adelina M. Uypeckcuat, Sarah Spencer, Jo Wick, H. Duane Smith,

Frontiers in Oncology

Abstract

NCT00799240, clinicaltrials.gov.

References

	Year	Citations

Page 1